Targeted KRAS suppression in colorectal cancer via in vivo self-assembled siRNAs encapsulated in endogenous small extracellular vesicles.
KRAS is a prevalent oncogenic driver whose therapeutic targeting has remained challenging beyond the G12C mutation. Here, we developed a gene circuit platform that enables the in vivo self-assembly of small extracellular vesicles (sEVs) encapsulating KRAS-specific siRNAs for broad targeting of KRAS mutants. The system...